Byrd JC et al. Chronic lymphocytic leukemia. Hematology (Am Soc Hematol Educ Program) 2004;1:163-83. Abstract

Campbell P, Marcus R. Monoclonal antibody therapy for lymphoma. Blood Rev 2003;17(3):143-52. Abstract

Dearden CE et al. Alemtuzumab in T-cell malignancies. Med Oncol 2002;19(Suppl):S27-32. Abstract

Eisenbeis CF et al. Combination immunotherapy of B-cell non-Hodgkin’s lymphoma with rituximab and interleukin-2: A preclinical and phase I study. Clin Cancer Res 2004;10(18 pt 1):6101- 10. Abstract

Enblad G et al. A pilot study of alemtuxumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004;103(8):2920-4. Abstract

Gibbs SD Et al. Alemtuzumab: Effective monotherapy for simultaneous B-cell chronic lymphocytic leukemia and Sezary syndrome. Eur J Haemotol 2004;73(6):447-9. Abstract

Gupta V et al. Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning. Bone Marrow Transplant 2005;[Epub ahead of print]. Abstract

Knauf W et al. Remission induction using alemtuzumab can permit chemotherapy-refractory chronic lymphocytic leukemia (CLL) patients to undergo allogenic stem cell transplantation. Leuk Lymphoma 2004;45(12):2455-8. Abstract

Lin TS, Byrd JC. Monoclonal antibody therapy in lymphoid leukemias. Adv Pharmacol 2004;51:127-67. No abstract available

Liu NS, O’brien S. Monoclonal antibodies in the treatment of chronic lymphocytic leukemia. Med Oncol 2004;21(4):297-304. Abstract

Lin TS et al. Antibody therapy for chronic lymphocytic leukemia: A promising new modality. Hematol Oncol Clin North Am 2004;18(4):895-913. Abstract

Moreton P, Hillmen P. Alemtuzumab therapy in B-cell lymphoproliferative disorders. Semin Oncol 2003;30(4):493-501. Abstract

Nabhan C et al. A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphatic leukemia (CLL). Leuk Lymphona 2004;45(11):2269-73. Abstract

Nosari A et al. Infectious toxicity using alemtuzumab. Haematologica 2004;89(12):1415-18. No abstract available

Rassenti LZ et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004;351(9):893-901. Abstract

Smolewski P et al. Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. Leuk Lymphoma 2005;46(1):87-100. Abstract

Thieblemont C et al. Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL). Leuk Lymphoma 2004;45(4):711-4. Abstract